


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED
領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

APPOINTMENT OF EXECUTIVE DIRECTOR

This announcement is made by Innovative Pharmaceutical Biotech Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

APPOINTMENT OF EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of the Company is pleased to announce the appointment of Ms. Huang He (“**Ms. Huang**”) as an executive director of the company with effect from 10 January 2017 (the “**Appointment**”).

The biological details of Ms. Huang are set out as follows:

Ms. Huang, aged 35, has over 10 years of experience in corporate and investment management as well as mergers and acquisitions in the People’s Republic of China (the “**PRC**”). From 13 October 2016 to 20 December 2016, Ms. Huang was the executive director of Kong Shum Union Property Management (Holding) Limited (Stock Code : 8181), a company listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Ms. Huang is currently the legal representative and chairman of several companies that were incorporated in the PRC. Ms. Huang is currently an executive director of China Ocean Fishing Holdings Limited (stock code: 8047) whose shares are listed on the Growth Enterprise Market of The Stock Exchange.

Ms. Huang has entered into a service contract with the Company for a term of three-years. Ms. Huang is entitled to a Director's remuneration of HK\$50,000 per month pursuant to the service contract which is determined by arm's length negotiation between Ms. Huang and the Company with reference to her duties, responsibilities and the prevailing market conditions and is subject to review by the Remuneration Committee of the Company. The Appointment is also subject to retirement by rotation and re-election at the next following general meeting of the Company in accordance with the articles of association of the Company.

Ms. Huang has confirmed that she does not have any interest (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) in the securities of the Company as at the date of this announcement.

Save as disclosed in this announcement, Ms. Huang held no other directorship in any listed public company in the last three years preceding the date of her appointment. Further, Ms. Huang does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Ms. Huang has not been involved in any of the events under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to his appointment as an executive director that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its warmest welcome to Ms. Huang for joining the Board.

By Order of the Board
Innovative Pharmaceutical Biotech Limited
Jiang Nian
Chairman

Hong Kong, 10 January 2017

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director), Mr. Gao Yuan Xing (executive director), Mr. Tang Rong (executive director), Ms. Huang He (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).